Published in TB and Outbreaks Week, May 29th, 2007
"This has been a productive quarter for us, highlighted by the government's decision to award Iomai a $128 million contract for the development of a dose-sparing booster patch that can be used to cut the amount of influenza vaccine required for protection in the event of a flu pandemic. We have already achieved the first milestone under that contract, which was the submission of a product development plan, on time," said Stanley C. Erck, President and Chief Executive Officer of Iomai. "We further validated our core technology -- transcutaneous...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week